About Marburg Disease

Key points

  • Marburg disease is a rare but severe hemorrhagic fever that can cause serious illness and death.
  • Symptoms can be similar to other tropical diseases, making diagnosis challenging.
  • There is no treatment or vaccine for Marburg disease.
  • The disease spreads through contact with infected animals or people.

Overview

Marburg disease is a rare, severe viral hemorrhagic fever which affects both people and other primates, like apes and monkeys. Caused by infection with orthomarburgviruses, Marburg virus or Ravn virus, the disease can lead to serious illness or death. Symptoms can appear suddenly and may include fever, rash, and severe bleeding.

Orthomarburgviruses are naturally found in the Egyptian rousette bat (Rousettus aegyptiacus) and can spread from bats to people. Marburg disease is most commonly found in sub-Saharan Africa.

A map showing Marburg disease outbreaks
Most Marburg disease outbreaks have occurred in Sub-Saharan Africa

Signs and symptoms

Initial Marburg disease signs and symptoms include:

  • Fever
  • Chills
  • Headache
  • Muscle aches
  • Rash with both flat and raised bumps, often on the torso
  • Chest pain
  • Sore throat
  • Nausea, vomiting, and diarrhea

As the disease advances, symptoms can become more severe, including liver failure, delirium, shock, bleeding (hemorrhaging), and multi-organ dysfunction.

How long it takes for signs to show

People with Marburg disease usually start getting sick 2-21 days after they were infected with the virus.

Risk factors

Those most at risk for Marburg disease include:

  • People in contact with Egyptian rousette bats or their excretions
  • People caring for individuals sick with Marburg disease without proper protective equipment
  • People in contact with infected non-human primates

How it spreads

Marburg disease is spread from infected Egyptian rousette bats to people. The virus is found in the saliva, urine, and feces of infected bats. Once the disease has "spilled over" from wildlife to people, those who are sick can spread the disease to other people.

Someone can become infected with Marburg disease if they have contact (such as through broken skin or mucous membranes in the eyes, nose, or mouth) with:

  • Body fluids of a person who is sick with or died from Marburg virus disease
  • Objects contaminated with their fluids like clothes, bedding, needles and equipment
  • Semen from a man who has recovered from infection with Marburg virus disease

Prevention

To prevent Marburg disease

  • Avoid contact with blood and body fluids of people who are sick.
  • Avoid contact with semen from a person who recovered from Marburg virus disease until testing shows that the virus is gone from their semen.
  • Do not handle items that may have come in contact with an infected person's body fluids.
  • Avoid contact with Egyptian rousette bats and non-human primates if in areas where Marburg disease is found.

Diagnosis

The following tests can be used for patients who had a possible exposure to an orthomarburgvirus and begin to show signs and symptoms of Marburg disease:

  • Polymerase chain reaction (PCR)
  • IgM-capture ELISA
  • Antigen-capture ELISA testing
  • Virus isolation in high-containment laboratories

Treatment and recovery

Currently, there are no licensed treatments for Marburg disease. Treatment is limited to supportive care. This includes rest, hydration, managing oxygen status and blood pressure, and treatment of secondary infections.

Expected outcomes

Marburg disease is a serious, deadly disease. Between 20-90 percent of people with the disease will die.

What CDC is doing

To combat Marburg disease, CDC:

  • Responds to Marburg disease outbreaks around the globe.
  • Provides infection prevention and control guidance.
  • Offers confirmatory diagnostic testing.
  • Conducts ongoing research to better understand the disease.
  • Adjemian J, Farnon EC, Tschioko F, et al. Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda districts, Uganda, 2007. Journal of Infectious Diseases. 2011;204(Suppl 3):S796-99.
  • Amman BR, Carroll SA, Reed ZD, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human iInfection. PLoS Pathogens. 2012;8(10):e1002877.
  • Bausch DG, Borchert M, Grein T, et al. Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo. Emerging Infectious Diseases. 2003;9(12):1531-1537.
  • Bausch DG , Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert Review of Vaccines. 2007;6(1):57-74.
  • Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. New England Journal of Medicine. 2006;355:9099-19.
  • Bausch DG, Sprecher AG, Jeffs B, et al. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Research. 2008;78(1):150-61.
  • Brauburger K, Hume AJ, Muhlberger E, et al. Forty-five years of Marburg virus research. Viruses. 2012;4(10):1878-1927.
  • Centers for Disease Control and Prevention. Imported case of Marburg hemorrhagic fever – Colorado, 2008. Morbidity and Mortality Weekly Report. 2009;58(49):1377-81.
  • Gear JHS. Haemorrhagic fevers of Africa: an account of two recent outbreaks. Journal of the South African Veterinary Association. 1977;48(1):5-8.
  • Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Reviews in Medical Virology. 2010;20(6):344-57.
  • Hensley LE, Alves DA, Geisbert JB, et al. TW. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. Journal of Infectious Diseases. 2011;204(Suppl 3):S1021-31.
  • Johnson ED, Johnson BK, Silverstein D, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Archives of Virology. 1996;11(Suppl):101-14.
  • Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. Journal of Infectious Diseases. 2011;204(Suppl 3):S810-16.
  • Kuming BS, Kokoris N. Uveal involvement in Marburg virus disease. British Journal of Ophthalmology. 1977; 61, 265-266.
  • MacNeil A, Rollin PE. Ebola and Marburg Hemorrhagic Fevers: Neglected Tropical Diseases? PLOS Neglected Tropical Diseases. 2012;6(6):e1546.
  • Martini GA, Schmidt HA. Spermatogenic transmission of the "Marburg virus". Klin Wochenschr. 1968; 46(7):398-400.
  • Martini GA, Knauff HG, Schmidt HA, et al. A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease. German Medical Monthly. 1968;13(10):457-70.
  • Mehedi M, Groseth A, Feldmann H, et al. Clinical aspects of Marburg hemorrhagic fever. Future Virology 2011;6(9):1091-106.
  • Nyakarahuka L, Shoemaker TR, Balinandi S, et al. (2019) Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings. PLoS Negl Trop Dis 13(3): e0007257.
  • Rollin PE, Nichol ST, Zaki S, et al. Arenaviruses and filoviruses. In: Versalovic J, Carroll KC, Funke G, et al., eds. Manual of Clinical Microbiology. 10th ed. Washington, DC: ASM Press; 2011. 2. pp. 1514-29.
  • Smith LM, Hensley LE, Geisbert TW, et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. Journal of Infectious Diseases. 2013;208(2):310-18.
  • Swanepoel R, Smit SB, Rollin PE, et al. Studies of reservoir hosts for Marburg virus. Emerging Infectious Diseases. 2007;13(12):1847-51.
  • Teepe RG, Johnson BK, Ocheng D, et al. A probable case of Ebola virus haemorrhagic fever in Kenya. East African Medical Journal. 1983;60(10):718-22.
  • Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathogens. 2009;5(7):e1000536.
  • Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. Journal of Virology. 2006; 80(13):6497-516.
  • Towner JS, Pourrut X, Albariño CG et al. Marburg Virus Infection Detected in a Common African Bat. PLoS One. 2007;8(8)e764.
  • Warren TK , Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Medicine. 2010;16(9):991-94.